SARS-COV-1 also used ACE2 receptors. In fact your article specifically discusses that, and suggests there was potential to use SARS-COV-1 vaccine development to create SARS-COV-2 vaccines.
The ACE2 receptor affinity is not novel.
The ACE2 receptor affinity is not novel.